Starved and asphyxiated: How can CD8+ T cells within a tumor microenvironment prevent tumor progression

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Zhang, Ying ^a,b   Ertl, Hildegund C J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

CD8+ T cell metabolism; Fatty acid metabolism; Hypoxia; Ketone bodies; Lack of glucose; Metabolic stress; Tumor microenvironment; Tumor infiltrating lymphocytes

Indexed keywords

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; HUMAN; HYPOGLYCEMIA; HYPOXIA; IMMUNE RESPONSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84962506335     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00032     Document Type: Article

References (88)

1. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5:844-52. doi:10.1038/nri1710.
2. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0.
3. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 64:3892-9. doi:10.1158/0008-5472.CAN-03-2904.
4. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 3:a014217-014217. doi:10.1101/cshperspect.a014217.
5. Antico Arciuch VG, Russo MA, Kang KS, Di Cristofano A. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res (2013) 73:5459-72. doi:10.1158/0008-5472.CAN-13-1429.
6. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13:907-15. doi:10.1038/ni.2386.
7. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol (2015) 36:81-91. doi:10.1016/j.it.2014.12.005.
8. O'Sullivan D, van der Windt GJW, Huang SC-C, Curtis JD, Chang C-H, Buck MD, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity (2014) 41:75-88. doi:10.1016/j.immuni.2014.06.005.
9. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543-53. doi:10.1128/MCB.25.21.9543-9553.2005.
10. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/ncomms7692.
11. Charlton JJ, Chatzidakis I, Tsoukatou D, Boumpas DT, Garinis GA, Mamalaki C. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J Immunol (2013) 190:6104-14. doi:10.4049/jimmunol.1201617.
12. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439:682-7. doi:10.1038/nature04444.
13. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2009) 10:29-37. doi:10.1038/ni.1679.
14. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 25:214-21. doi:10.1016/j.coi.2012.12.003.
15. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 14:561-84. doi:10.1038/nrd4591.
16. Ruiz-Cabello F, Nevot MAL, Garrido F. MHC class I and II gene expression on human tumors. Adv Exp Med Biol (1988) 233:119-28. doi:10.1007/978-1-4899-5037-6_14.
17. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 26:225-39. doi:10.1007/s10555-007-9055-1.
18. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci U S A (1994) 91:6496-500. doi:10.1073/pnas.91.14.6496.
19. Kim J-W, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 3:177-85. doi:10.1016/j.cmet.2006.02.002.
20. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 22:657-82. doi:10.1146/annurev.immunol.22.012703.104731.
21. Atkuri KR, Herzenberg LA, Herzenberg LA. Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc Natl Acad Sci U S A (2005) 102:3756-9. doi:10.1073/pnas.0409910102.
22. Larbi A, Zelba H, Goldeck D, Pawelec G. Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol (2010) 87:265-73. doi:10.1189/jlb.0509304.
23. Zuckerberg AL, Goldberg LI, Lederman HM. Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med (1994) 22:197-203. doi:10.1097/00003246-199402000-00008.
24. Kim H, Peng G, Hicks JM, Weiss HL, Van Meir EG, Brenner MK, et al. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther (2008) 16:599-606. doi:10.1038/sj.mt.6300391.
25. Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH, et al. Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A (2005) 102:17071-6. doi:10.1073/pnas.0506070102.
26. Choukèr A, Thiel M, Lukashev D, Ward JM, Kaufmann I, Apasov S, et al. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med (2008) 14:116-23. doi:10.2119/2007-00075.Chouker.
27. Meehan R, Duncan U, Neale L, Taylor G, Muchmore H, Scott N, et al. Operation Everest II: alterations in the immune system at high altitudes. J Clin Immunol (1988) 8:397-406. doi:10.1007/BF00917156.
28. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GRS, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol (2007) 177:1029-36. doi:10.1083/jcb.200609074.
29. Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal (2013) 18:1497-534. doi:10.1089/ars.2011.4073.
30. Guo J, Lu W, Shimoda LA, Semenza GL, Georas SN. Enhanced interferon-gamma gene expression in T cells and reduced ovalbumin-dependent lung eosinophilia in hypoxia-inducible factor-1-alpha-deficient mice. Int Arch Allergy Immunol (2009) 149:98-102. doi:10.1159/000189191.
31. Lukashev D, Klebanov B, Kojima H, Grinberg A, Berenfeld L, Wenger RH, et al. Cutting edge: hypoxia-inducible factor 1 and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 177:4962-5. doi:10.4049/jimmunol.177.8.4962.
32. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol (2013) 14:1173-82. doi:10.1038/ni.2714.
33. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 209:2441-53. doi:10.1084/jem.20112607.
34. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 97:1573-81. doi:10.1002/cncr.11246.
35. Swinson DEB, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer (2004) 111:43-50. doi:10.1002/ijc.20052.
36. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res (2014) 74:665-74. doi:10.1158/0008-5472.CAN-13-0992.
37. Fang H-Y, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, et al. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood (2009) 114:844-59. doi:10.1182/blood-2008-12-195941.
38. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol (2009) 9:609-17. doi:10.1038/nri2607.
39. Chang C-H, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell (2015) 162:1-14. doi:10.1016/j.cell.2015.08.016.
40. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol (2005) 174:4670-7. doi:10.4049/jimmunol.174.8.4670.
41. Cham CM, Driessens G, O'Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 38:2438-50. doi:10.1002/eji.200838289.
42. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476.
43. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab (2014) 20:61-72. doi:10.1016/j.cmet.2014.05.004.
44. Ho P-C, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell (2015) 162:1217-28. doi:10.1016/j.cell.2015.08.012.
45. Warburg O. On the origin of cancer cells. Science (1956) 123:309-14. doi:10.1126/science.123.3191.309.
46. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 109:3812-9. doi:10.1182/blood-2006-07-035972.
47. Chang C-H, Curtis JD, Maggi LB, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 153:1239-51. doi:10.1016/j.cell.2013.05.016.
48. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation. Oncogene (2005) 24:4165-73. doi:10.1038/sj.onc.1208622.
49. Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, Yurchenko E, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity (2015) 42:41-54. doi:10.1016/j.immuni.2014.12.030.
50. O'Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature (2013) 493:346-55. doi:10.1038/nature11862.
51. O'Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol (2015) 36:71-80. doi:10.1016/j.it.2014.12.004.
52. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 123:4479-88. doi:10.1172/JCI69589.
53. Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, Hieshima K, et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest (2001) 108:871-8. doi:10.1172/JCI13296.
54. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol (2008) 84:949-57. doi:10.1189/jlb.0108024.
55. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res (2015) 75:296-305. doi:10.1158/0008-5472.CAN-14-2277.
56. Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab (2013) 18:153-61. doi:10.1016/j.cmet.2013.05.017.
57. Zhang F. Dysregulated lipid metabolism in cancer. World J Biol Chem (2012) 3:167. doi:10.4331/wjbc.v3.i8.167.
58. Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells (2010) 2:103-13. doi:10.4252/wjsc.v2.i5.103.
59. Byersdorfer CA, Tkachev V, Opipari AW, Goodell S, Swanson J, Sandquist S, et al. Effector T cells require fatty acid metabolism during murine graft-versus-host disease. Blood (2013) 122:3230-7. doi:10.1182/blood-2013-04-495515.
60. Byersdorfer CA. The role of fatty acid oxidation in the metabolic reprograming of activated T-cells. Front Immunol (2014) 5:161. doi:10.3389/fimmu.2014.00641.
61. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab (2014) 25:42-52. doi:10.1016/j.tem.2013.09.002.
62. Takahashi S, Iizumi T, Mashima K, Abe T, Suzuki N. Roles and regulation of ketogenesis in cultured astroglia and neurons under hypoxia and hypoglycemia. ASN Neuro (2014) 6:1759091414550997. doi:10.1177/1759091414550997.
63. Curi R, Williams JF, Newsholme EA. Formation of ketone bodies by resting lymphocytes. Int J Biochem (1989) 21:1133-6. doi:10.1016/0020-711X(89)90055-4.
64. Curi R, Williams JF, Newsholme EA. Pyruvate metabolism by lymphocytes: evidence for an additional ketogenic tissue. Biochem Int (1989) 19:755-67.
65. Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 203:2749-61. doi:10.1084/jem.20060710.
66. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem (1995) 270:17513-20. doi:10.1074/jbc.270.29.17513.
67. van der Windt GJW, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev (2012) 249:27-42. doi:10.1111/j.1600-065X.2012.01150.x.
68. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev (2011) 25:1041-51. doi:10.1101/gad.1987211.
69. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med (2015) 212:1125-37. doi:10.1084/jem.20142237.
70. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 257:56-71. doi:10.1111/imr.12132.
71. Maus MV, Powell DJ. Chimeric antigen receptor T-cells: new approaches to improve their efficacy and reduce toxicity. Cancer J (2015) 21:475-9. doi:10.1097/PPO.0000000000000155.
72. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5:177ra38. doi:10.1126/scitranslmed.3005930.
73. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 368:1509-18. doi:10.1056/NEJMoa1215134.
74. Kakarla S, Gottschalk S. CAR T cells for solid tumors. Cancer J (2014) 20:151-5. doi:10.1097/PPO.0000000000000032.
75. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther (2007) 15:825-33. doi:10.1038/sj.mt.6300104.
76. Lamers CHJ. Treatment of metastatic renal cell carcinoma with autologous t-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 24:e20-2. doi:10.1200/JCO.2006.05.9964.
77. Curran KJ, Brentjens RJ. Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol (2015) 33:1703-6. doi:10.1200/JCO.2014.60.3449.
78. Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. OncoImmunology (2014) 3:e970027. doi:10.4161/21624011.2014.970027.
79. Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin Immunol (2015). doi:10.1016/j.smim.2015.11.003.
80. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. OncoImmunology (2013) 2:e26286. doi:10.4161/onci.26286.
81. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther (2012) 11:1672-82. doi:10.1158/1535-7163.MCT-12-0131.
82. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2013) 45:104-8. doi:10.1038/ng.2471.
83. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 115:1616-26. doi:10.1172/JCI24480.
84. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 201:139-48. doi:10.1084/jem.20041057.
85. Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol (2007) 19:1213-21. doi:10.1093/intimm/dxm093.
86. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J (2010) 16:392-8. doi:10.1097/PPO.0b013e3181eacbc4.
87. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 102:9571-6. doi:10.1073/pnas.0503726102.
88. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 17:5343-52. doi:10.1158/1078-0432.CCR-11-0503.